KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Gains from Investment Securities (2016 - 2025)

AbbVie (ABBV) has disclosed Gains from Investment Securities for 14 consecutive years, with $2.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 17.3% to $2.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $6.5 billion, a 116.5% increase, with the full-year FY2025 number at $6.5 billion, up 116.5% from a year prior.
  • Gains from Investment Securities was $2.4 billion for Q4 2025 at AbbVie, down from $2.8 billion in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $2.9 billion in Q4 2024 to a low of -$3.4 billion in Q4 2023.
  • A 5-year average of $446.7 million and a median of $181.0 million in 2022 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 19900.0% in 2021; the steepest drop was 13100.0% in 2021.
  • AbbVie's Gains from Investment Securities stood at $28.0 million in 2021, then plummeted by 5175.0% to -$1.4 billion in 2022, then crashed by 141.52% to -$3.4 billion in 2023, then soared by 185.23% to $2.9 billion in 2024, then dropped by 17.3% to $2.4 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Gains from Investment Securities are $2.4 billion (Q4 2025), $2.8 billion (Q3 2025), and $1.3 billion (Q2 2025).